Oxford Nanopore Technologies PLC on Friday said its nanopore sequencing can now deliver accurate data outputs and capture all variant types in one experiment and on one platform.

Oxford Nanopore is an Oxford-based company developing and selling nanopore sequencing products. Executives were provided an update on the company’s nanopore sensing platform at the annual London Calling conference.

The company discussed its ‘best of both’ sequencing chemistry, which combines the latest R10.4.1 flow cells with the Kit14 to deliver high-accuracy, high-output sequencing data.

‘The move to R10 and Kit14 combines the best of the previous capabilities: very high accuracy and outputs. Early community evidence is showing a strong performance with the new kit and flow cells,’ Oxford Nanopore noted.

Earlier this month, the company said its sequencing technology was selected for the 1000 Genomes Project, led by University of Washington and Seattle Children’s Hospital.

The technology will be used by the 1000 Genomes Project initially to sequence 500 of the project’s samples.

The project’s goal ‘is to gain more scientific insights from the comprehensive genomic dataset and to create a catalogue of structural variation from a diverse set of individuals,’ Oxford Nanopore said.

Oxford Nanopore shares were up 4.2% at 307.24 pence each on Friday morning in London.

Copyright 2022 Alliance News Limited. All Rights Reserved.